OssDsign

OssDsign OCF Margin

The Operating Cash Flow Margin of OssDsign (OSSD.ST) as of Nov 3, 2026 is -35.54 %. In the previous year, Operating Cash Flow Margin was -46.57 % — a change of -23.68% (higher).

OCF Margin

-35.54 %

YoY

-23.68%

Last updated:

Operating Cash Flow Margin of OssDsign is 2025 -35.54 % . Operating Cash Flow Margin of OssDsign was 2024 -46.57 % . It decreases by -23.68% higher compared to the previous year.

The OssDsign OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-497.98 SEK
Jan 1, 2019
-513.20 SEK
Jan 1, 2020
-318.02 SEK
Jan 1, 2021
-283.00 SEK
Jan 1, 2022
-156.58 SEK
Jan 1, 2023
-83.73 SEK
Jan 1, 2024
-46.57 SEK
Jan 1, 2025
-35.54 SEK
The OssDsign OCF Margin history
YEAROCF MarginYoY
-35.54 %-23.68%
-46.57 %-44.38%
-83.73 %-46.53%
-156.58 %-44.67%
-283.00 %-11.01%
-318.02 %-38.03%
-513.20 %+3.06%
-497.98 %-5.81%
-528.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OssDsign Stock analysis

What does OssDsign do? OssDsign AB develops and sells medical technology products, focusing on implantable solutions for bone healing, particularly in skull surgery. Its primary product, Craniomosaic, is an implant for skull defect repair (cranioplasty), while it also develops bioceramic implants for facial bone augmentation. The company uses proprietary bioceramic technologies that integrate with tissues and support bone ingrowth. Customers include neurosurgeons, craniofacial, and maxillofacial surgeons who purchase these products for surgical procedures. The company generates revenue through the development and sales of its medical technology products, specifically Craniomosaic and bioceramic implants for facial bone augmentation. These products are sold to surgeons specializing in skull and facial bone procedures. The firm’s focus on proprietary bioceramic technologies differentiates its offerings in the medical device market, targeting healthcare professionals who require advanced solutions for bone healing challenges. OssDsign AB’s business model centers on selling implantable medical devices developed using its unique bioceramic technologies. The company’s main customers are neurosurgeons, craniofacial surgeons, and maxillofacial surgeons who use Craniomosaic and facial bone augmentation implants during surgical operations. Revenue is derived from the direct sale of these products to medical professionals for clinical applications in bone healing and reconstruction. OssDsign is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OssDsign stock

Operating Cash Flow Margin of OssDsign is -35.54 % in 2025.

Operating Cash Flow Margin of OssDsign changed from -46.57 % to -35.54 %, representing a -23.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin OssDsign since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's OssDsign with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — OssDsign

All Key Metrics — OssDsign